EQ实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need...

Stats
今日成交量	80 121.00
平均成交量	367 004
市值	60.29M
EPS	$0 ( 2024-03-28 )
下一个收益日期	( $-0.170 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.50
ATR14	$0.0230 (1.35%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Tom Penny	Sell	0	Common Stock
2024-03-06	Tom Penny	Sell	45 000	Employee Stock Option (right to buy)
2024-03-06	Tom Penny	Sell	40 000	Employee Stock Option (right to buy)
2024-03-06	Tom Penny	Sell	60 000	Employee Stock Option (right to buy)
2024-03-06	Tom Penny	Sell	40 000	Employee Stock Option (right to buy)

INSIDER POWER
61.76
Last 97 transactions
Buy: 3 858 069 \| Sell: 577 250

音量相关性

長: 0.01 (neutral)

短: 0.79 (moderate)

Signal:(46.106) Neutral

Equillium Inc 相关性

10 最正相关
GRNV	0.919
EGRX	0.917
AXTI	0.917
VVOS	0.915
FVE	0.909
BCRX	0.906
NVEE	0.904
OTRK	0.903
BFRI	0.903
CNSP	0.898

10 最负相关
AMRB	-0.94
LSTR	-0.939
RMBS	-0.937
LSCC	-0.936
MCHP	-0.932
KE	-0.93
SNSR	-0.926
SMH	-0.923
SOXX	-0.918
GRID	-0.917

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Equillium Inc 相关性 - 货币/商品

0.29
( neutral )

0.00
( neutral )

0.51
( weak )

0.00
( neutral )

-0.14
( neutral )

Equillium Inc 财务报表

Annual	2023
营收:	$36.08M
毛利润:	$35.96M (99.65 %)
EPS:	$-0.380

FY	2023
营收:	$36.08M
毛利润:	$35.96M (99.65 %)
EPS:	$-0.380

FY	2022
营收:	$15.76M
毛利润:	$15.64M (99.25 %)
EPS:	$-3.19

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.579

Financial Reports:

No articles found.

Equillium Inc

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.